旅行疫苗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球旅行疫苗市场规模达49亿美元，预计2034年将以9.9%的复合年增长率成长，达到121亿美元。受全球健康意识提升、疫苗研发快速推进以及国际旅行模式演变等因素的影响，该市场发展势头强劲。人们对区域性疾病风险以及疫苗接种在境外预防疾病中作用的认识不断提高，正在推动疫苗的广泛需求。政府的卫生政策、教育工作以及数位健康平台正在强化疫苗在旅行前规划中的关键作用。

随着全球旅游业復苏并呈现多样化，预防性免疫接种已成为维护公共卫生的关键组成部分，尤其是在医疗基础设施有限的地区。技术创新简化了物流流程，降低了成本，并延长了疫苗的保质期，从而提升了疫苗的生产和配送。这些变革推动了旅游疫苗在全球范围内的广泛应用，尤其是在医疗资源匮乏和高风险地区。旅行疫苗旨在保护旅行者免受狂犬病、伤寒、黄热病和肝炎等疾病的侵害。市场细分为单药疫苗和联合疫苗，透过公立和私人医疗管道分销。

单药疫苗市场在2024年的营收为29亿美元，预计到2034年将达到71亿美元，复合年增长率为9.7%。这类疫苗持续占据主导地位，得益于其精准的保护和较低的副作用风险，使其成为前往卫生条件差、疾病高发地区的旅行者的首选。伤寒和狂犬病等疾病的免疫接种通常根据目的地、旅行时间和当地医疗状况进行建议。

就疫苗类型而言，甲型肝炎疫苗在2024年的市占率为20.2%。其强劲的市场地位与其在预防食源性和水源性疾病方面发挥的重要作用息息相关，尤其是在拉丁美洲、亚洲和非洲等卫生状况依然堪忧的地区。即使是短暂的旅行也可能带来风险，尤其是对于品嚐当地美食或入住非商业性住宿的旅客而言。由于传播风险较高，全球卫生部门强烈建议大多数国际旅客接种甲型肝炎疫苗作为标准措施。

美国旅行疫苗市场在2024年创收19亿美元，预计2025年至2034年期间的复合年增长率将达到9.3%。这一增长与国际出境人数的增加以及积极的公共卫生措施相一致。联邦机构正在透过更新指南和进行推广活动来鼓励旅行相关的免疫接种，从而支持市场扩张。出境旅游的成长，加上疾病意识的提高，持续推动全美疫苗接种的普及。

全球旅行疫苗市场的领导者包括明治集团、Dynavax Technologies、印度血清研究所、赛诺菲、葛兰素史克公司 (GSK)、Valneva SE、Bharat Biotech、辉瑞、CSL、Emergent BioSolutions、默克和 Bavarian Nordic。为了保持竞争优势，旅行疫苗产业的公司正在实施以创新、扩张和可及性为中心的策略。对 mRNA 和单剂量解决方案等先进技术的投资有助于提高疫苗效力和给药效率。各公司正在提升生产可扩展性，以满足全球需求，尤其是在疫苗取得受限的地区。他们正在利用与公共卫生机构和旅行健康服务提供者的策略合作伙伴关係来提高知名度和分销范围。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 出境旅游和国际游不断增加
    • 预防措施意识不断增强
    • 疫苗配方和生产效率的进步
  • 产业陷阱与挑战
    • 物流和基础设施挑战
    • 严格的监管审批流程
  • 市场机会
    • 客製化疫苗和组合疫苗
    • 旅游业蓬勃发展
• 成长潜力分析
• 管道分析
• 技术格局
  • 当前的技术趋势
  • 新兴技术
• 监管格局
• 差距分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
  • 北美洲
  • 欧洲
  • 亚太地区
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展

第五章：市场估计与预测：按疫苗类型，2021-2034

• 主要趋势
• 单药疫苗
• 联合疫苗

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

• 主要趋势
• 甲型肝炎
• 脑膜炎球菌疾病
• 流感
• 白喉、百日咳、破伤风（DPT）
• 狂犬病
• 黄热病
• 伤寒
• 麻疹、腮腺炎和德国麻疹 (MMR)
• B型肝炎
• 其他疾病类型

第七章：市场估计与预测：按应用，2021 - 2034 年

• 主要趋势
• 出境旅游
• 国内旅游

第八章：市场估计与预测：按年龄组，2021 - 2034 年

• 主要趋势
• 儿科
• 成人

第九章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
  • 民众
  • 私人的
• 专科诊所
• 其他最终用途

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Bavarian Nordic
• Bharat Biotech
• CSL
• Dynavax Technologies
• Emergent BioSolutions
• GlaxoSmithKline plc (GSK)
• Meiji Group
• Merck
• Pfizer
• Sanofi
• Serum Institute of India
• Valneva SE

The Global Travel Vaccines Market was valued at USD 4.9 billion in 2024 and is estimated to grow at a CAGR of 9.9% to reach USD 12.1 billion by 2034. This market is gaining momentum due to a mix of global health awareness, rapid advancements in vaccine development, and evolving international travel patterns. Increasing recognition of regional disease risks and the role of vaccination in preventing illness while abroad is fueling widespread demand. Government health policies, education efforts, and digital health platforms are reinforcing the critical role vaccines play in pre-travel planning.

As global travel recovers and diversifies, preventive immunization becomes a crucial component in maintaining public health, particularly in areas with limited healthcare infrastructure. Technology is enhancing vaccine production and delivery through innovations that streamline logistics, reduce costs, and improve shelf life. These shifts are enabling wider adoption of travel vaccines globally, especially in underserved and high-risk areas. Travel vaccines are administered to protect travelers from infections like rabies, typhoid, yellow fever, and hepatitis. The market is segmented into mono and combination vaccines, distributed through both public and private healthcare channels.

The mono vaccines segment generated USD 2.9 billion in 2024 and is forecast to reach USD 7.1 billion by 2034 at a CAGR of 9.7%. Their continued dominance stems from targeted protection and lower risk of side effects, making them a preferred choice for travelers heading to areas with poor sanitation and high disease prevalence. Immunizations for diseases like typhoid and rabies are often recommended depending on the destination, duration of travel, and local healthcare conditions.

In terms of vaccine type, the Hepatitis A segment held a 20.2% share in 2024. Its strong position is linked to its essential role in protecting against food and water-borne illness, particularly in regions across Latin America, Asia, and Africa where sanitation remains a major concern. Even short visits can pose a risk, especially for those consuming local cuisine or staying in non-commercial accommodations. Due to the high transmission risk, global health authorities strongly recommend Hepatitis A vaccination as a standard measure for most international travelers.

United States Travel Vaccines Market generated USD 1.9 billion in 2024 and is expected to grow at a CAGR of 9.3% between 2025 and 2034. This growth aligns with increasing international departures and proactive public health initiatives. Federal agencies are supporting market expansion by encouraging travel-related immunization through updated guidelines and outreach efforts. The increase in outbound tourism, combined with rising disease awareness, continues to drive vaccine uptake across the country.

Leading players in the Global Travel Vaccines Market include Meiji Group, Dynavax Technologies, Serum Institute of India, Sanofi, GlaxoSmithKline plc (GSK), Valneva SE, Bharat Biotech, Pfizer, CSL, Emergent BioSolutions, Merck, and Bavarian Nordic. To maintain a competitive advantage, companies in the travel vaccines sector are implementing strategies centered around innovation, expansion, and accessibility. Investments in advanced technologies like mRNA and single-dose solutions are helping improve vaccine efficacy and delivery. Firms are enhancing their manufacturing scalability to meet global demand, particularly in regions with limited access. Strategic partnerships with public health institutions and travel health providers are being leveraged to increase awareness and distribution reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Disease type trends
  • 2.2.4 Application trends
  • 2.2.5 Age group trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising outbound or international travel
    • 3.2.1.2 Growing awareness of preventive measures
    • 3.2.1.3 Advancements in vaccine formulation and production efficiency
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Logistical & infrastructure challenges
    • 3.2.2.2 Stringent regulatory approval process
  • 3.2.3 Market opportunities
    • 3.2.3.1 Customized & combination vaccines
    • 3.2.3.2 Growing travel and tourism
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Regulatory landscape
• 3.7 Gap analysis
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 North America
  • 4.3.2 Europe
  • 4.3.3 Asia Pacific
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Mono vaccines
• 5.3 Combination vaccines

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hepatitis A
• 6.3 Meningococcal diseases
• 6.4 Influenza
• 6.5 Diphtheria, pertussis, tetanus (DPT)
• 6.6 Rabies
• 6.7 Yellow fever
• 6.8 Typhoid
• 6.9 Measles, mumps, and rubella (MMR)
• 6.10 Hepatitis B
• 6.11 Other disease types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Outbound travel
• 7.3 Domestic travel

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
  • 9.2.1 Public
  • 9.2.2 Private
• 9.3 Specialty clinics
• 9.4 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bavarian Nordic
• 11.2 Bharat Biotech
• 11.3 CSL
• 11.4 Dynavax Technologies
• 11.5 Emergent BioSolutions
• 11.6 GlaxoSmithKline plc (GSK)
• 11.7 Meiji Group
• 11.8 Merck
• 11.9 Pfizer
• 11.10 Sanofi
• 11.11 Serum Institute of India
• 11.12 Valneva SE